ThZeal - The Zeal

N-PX 1 tm2219798d2_npx.htm N-PX

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB APPROVAL
		OMB Number: 3235-0582
		Expires: July 31, 2024
		Estimated average burden
		hours per response........4

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number 811- 06565

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19^th Floor, Boston, MA	02110
(Address of principal executive offices)	(Zip code)

Laura Woodward

Tekla Life Sciences Investors

100 Federal Street, 19^th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant’s telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 7/1/21-6/30/22

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

Vote Summary

ACADIA PHARMACEUTICALS, INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	07-Jun-2022
Record Date	22-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Laura A. Brege		For	For
	2.	Stephen R. Davis		For	For
	3.	Elizabeth A. Garofalo		For	For
2.	To approve an amendment to the Company's 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,000,000 shares.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.		Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Security	00650F109	Meeting Type	Annual
Ticker Symbol	ADPT	Meeting Date	10-Jun-2022
Record Date	14-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Chad Robins	Management	For	For
1.2	Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Kevin Conroy	Management	For	For
1.3	Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Dr. Michael Pellini	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our year ending December 31, 2022.	Management	For	For

ADICET BIO, INC.

Security	007002108	Meeting Type	Annual
Ticker Symbol	ACET	Meeting Date	02-Jun-2022
Record Date	05-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Aya Jakobovits		For	For
	2.	Chen Schor		For	For
2.	To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

AFFIMED N.V

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	22-Jun-2022

Record Date

25-May-2022

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Adoption of the Statutory Annual Accounts for the financial year 2021	Management	For	For
4.	Discharge of the managing directors for their management during the financial year 2021	Management	For	For
5.	Discharge of the supervisory directors for their supervision during the financial year 2021	Management	For	For
6b.	Amendment of the Remuneration Policy for the Management Board	Management	For	For
6c.	Amendment of the Remuneration Policy for the Supervisory Board	Management	For	For
7.	Reappointment of Dr. Bernhard Ehmer as a supervisory director	Management	For	For
8.	Appointment of the auditor for the financial year 2022	Management	For	For
9.	Authorization to acquire shares	Management	For	For

ALKERMES PLC

Security	G01767105	Meeting Type	Special
Ticker Symbol	ALKS	Meeting Date	13-May-2022
Record Date	13-Apr-2022

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To approve certain amendments to the Company's Articles of Association to provide for plurality voting for contested elections.		Management		For		For

ALKERMES PLC

Security	G01767105	Meeting Type	Annual
Ticker Symbol	ALKS	Meeting Date	07-Jul-2022
Record Date	01-Jun-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director: Emily Peterson Alva	Management	For	For
1B.	Election of Class II Director: Cato T. Laurencin, M.D., Ph.D.	Management	For	For
1C.	Election of Class II Director: Brian P. McKeon	Management	For	For
1D.	Election of Class II Director: Christopher I. Wright M.D., PH.D.	Management	For	For
2.	To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.	Management	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.	Management	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	Management	For	For
5.	To renew Board authority to allot and issue shares under Irish law.	Management	For	For
6.	To renew Board authority to disapply the statutory pre- emption rights that would otherwise apply under Irish law.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	18-May-2022
Record Date	28-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director: Margaret A. Hamburg, M.D.	Management	For	For
1B.	Election of Class III Director: Colleen F. Reitan	Management	For	For
1C.	Election of Class III Director: Amy W. Schulman	Management	For	For
2.	To approve the amended and restated 2018 Stock Incentive Plan.	Management	For	For
3.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2022.	Management	For	For

ALTIMMUNE, INC.

Security	02155H200	Meeting Type	Annual
Ticker Symbol	ALT	Meeting Date	23-Sep-2021
Record Date	10-Aug-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Mitchel Sayare, Ph.D.		For	For
	2.	Vipin K. Garg, Ph.D.		For	For
	3.	David J. Drutz, M.D.		For	For
	4.	John M. Gill		For	For
	5.	Philip L. Hodges		For	For
	6.	Diane Jorkasky, M.D.		For	For
	7.	Wayne Pisano		For	For
	8.	Klaus O. Schafer MD MPH		For	For
2.	Vote to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021.		Management	For	For
3.	Hold an advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement.		Management	Against	Against
4.	Approve the authorization to adjourn the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the proposals.		Management	Against	Against

ALX ONCOLOGY HOLDINGS, INC.

Security	00166B105	Meeting Type	Annual
Ticker Symbol	ALXO	Meeting Date	14-Jun-2022
Record Date	18-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Itziar Canamasas, Ph.D.		For	For
	2.	Jack Nielsen		For	For
2.	Advisory vote to approve named executive officer compensation.		Management	For	For
3.	Advisory vote on the frequency of future advisory votes on named executive officer compensation.		Management	1 Year	For
4.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2022.		Management	For	For

AMGEN, INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	17-May-2022
Record Date	18-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. Wanda M. Austin	Management	For	For
1B.	Election of Director for a term of expiring at the 2023 annual meeting: Mr. Robert A. Bradway	Management	For	For
1C.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. Brian J. Druker	Management	For	For
1D.	Election of Director for a term of expiring at the 2023 annual meeting: Mr. Robert A. Eckert	Management	For	For
1E.	Election of Director for a term of expiring at the 2023 annual meeting: Mr. Greg C. Garland	Management	For	For
1F.	Election of Director for a term of expiring at the 2023 annual meeting: Mr. Charles M. Holley, Jr.	Management	For	For
1G.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. S. Omar Ishrak	Management	For	For
1H.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. Tyler Jacks	Management	For	For
1I.	Election of Director for a term of expiring at the 2023 annual meeting: Ms. Ellen J. Kullman	Management	For	For
1J.	Election of Director for a term of expiring at the 2023 annual meeting: Ms. Amy E. Miles	Management	For	For
1K.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. Ronald D. Sugar	Management	For	For
1L.	Election of Director for a term of expiring at the 2023 annual meeting: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2022.	Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	25-Aug-2021
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of Bridge Financing; Waiver of Protective Provisions and Right of First Offer		Management		For		For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	08-Oct-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Consent to Wind-down and Dissolution by the Stockholders	Management	For	For
2.	Enabling Power	Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	14-Feb-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	General Assignment for benefit of creditors	Management	For	For
2.	Voluntary dissolution of the company	Management	For	For

APELLIS PHARMACEUTICALS INC.

Security	03753U106	Meeting Type	Annual
Ticker Symbol	APLS	Meeting Date	01-Jun-2022
Record Date	05-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to hold office until the 2025 annual meeting: A. Sinclair Dunlop	Management	For	For
1.2	Election of Class II Director to hold office until the 2025 annual meeting: Alec Machiels	Management	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	To approve an advisory vote on executive compensation.	Management	For	For

ARCUTIS BIOTHERAPEUTICS, INC.

Security	03969K108	Meeting Type	Annual
Ticker Symbol	ARQT	Meeting Date	01-Jun-2022
Record Date	04-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director to hold office until the 2025 Annual Meeting: Bhaskar Chaudhuri, Ph.D.	Management	For	For
1b.	Election of Class II Director to hold office until the 2025 Annual Meeting: Howard Welgus, M.D.	Management	For	For
1c.	Election of Class II Director to hold office until the 2025 Annual Meeting: Sue-Jean Lin	Management	For	For
2.	To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.	Management	For	For
4.	To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For

ARDELYX, INC.

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	13-Jul-2022
Record Date	25-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Geoffrey A. Block, M.D.		For	For
	2.	David Mott		For	For
	3.	Michael Raab		For	For
2.	To grant our Board of Directors authority to effect a reverse stock split of our authorized common stock and issued and outstanding common stock by amending our Amended and Restated Certificate of Incorporation by September 15, 2022 and within a range of not less than 1-for-2 and not more than 1-for-10, if our Board of Directors deems it within our best interests.		Management	For	For
3.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022.		Management	For	For
4.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on- Pay").		Management	For	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Special
Ticker Symbol	ARNA	Meeting Date	02-Feb-2022
Record Date	30-Dec-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated December 12, 2021 (the "Merger Agreement"), by and among Arena Pharmaceuticals, Inc. ("Arena"), Pfizer Inc., and Antioch Merger Sub, Inc.	Management	For	For
2.	To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Arena's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.	Management	For	For
3.	To adjourn the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.	Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	10-May-2022
Record Date	20-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
3.	Advisory vote to approve the 2021 remuneration report	Management	For
4b.	Adoption of the 2021 annual accounts	Management	For
4d.	Allocation of losses of the Company in the financial year 2021 to the retained earnings of the Company	Management	For
4e.	Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2021	Management	For
5.	Re-appointment of Tim Van Hauwermeiren as executive director to the board of directors of the Company for a term of 4 years	Management	For
6.	Re-appointment of Peter Verhaeghe as non-executive director to the board of directors of the Company for a term of 2 years	Management	For
7.	Re-appointment of James Daly as non-executive director to the board of directors of the Company for a term of 4 years	Management	For
8.	Re-appointment of Werner Lanthaler as non-executive director to the board of directors of the Company for a term of 2 years	Management	For
9.	Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any.	Management	For
10.	Amendment of the articles of association of argenx SE to align with current Dutch law and practice and to grant proxy to each of the directors of the Company and employees of Freshfields Bruckhaus Deringer LLP in having the deed of amendment executed	Management	For
11.	Appointment of Deloitte Accountants B.V. as statutory auditor for the 2022 financial year.	Management	For

ARKUDA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Jul-2021
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Waiver of the need to satisfy the applicable Milestones associated with the Third Tranche Closing.		Management		For		For

ARKUDA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	25-Jan-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amended and Restated Certificate of Incorporation.	Management	For	For
2.	Sale and Issuance of Series B Preferred Stock.	Management	For	For
3.	Restated By Laws.	Management	For	For
4.	Idemnification Agreement.	Management	For	For
5.	Amendment No.2 to the 2018 Stock Option and Grant Plan.	Management	For	For
6.	Waiver of Premptive Rights and Anti-Dillution Rights.	Management	For	For
7.	General Resolutions.	Management	For	For

ARROWHEAD PHARMACEUTICALS, INC.

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	17-Mar-2022
Record Date	21-Jan-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Douglass Given	Management	For	For
1B.	Election of Director: Michael S. Perry	Management	For	For
1C.	Election of Director: Christopher Anzalone	Management	For	For
1D.	Election of Director: Marianne De Backer	Management	For	For
1E.	Election of Director: Mauro Ferrari	Management	For	For
1F.	Election of Director: Adeoye Olukotun	Management	For	For
1G.	Election of Director: William Waddill	Management	For	For
2.	To approve, in an advisory (non-binding) vote, the compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.	Management	For	For
3.	To approve the Arrowhead Pharmaceuticals, Inc. Non- Employee Director Compensation Plan.	Management	For	For
4.	To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2022.	Management	For	For

ARVINAS, INC.

Security	04335A105	Meeting Type	Annual
Ticker Symbol	ARVN	Meeting Date	16-Jun-2022
Record Date	19-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Linda Bain		For	For
	2.	John Houston, Ph.D.		For	For
	3.	Laurie S. Alsup, M.D.		For	For
2.	To approve, on an advisory basis, the Company's executive compensation.		Management	For	For
3.	Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Special
Ticker Symbol	ASND	Meeting Date	05-Nov-2021
Record Date	21-Oct-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The Board of Directors proposes that attorney-at-law Lars Lüthjohan Jensen is elected as chairman of the general meeting.	Management	For	For
2.	Election of Director: Nominees for Class I, with a term expiring at the annual general meeting to be held in 2023: James I. Healy, Jan Møller Mikkelsen, Lisa Morrison; Nominees for Class II, with a term expiring at the annual general meeting to be held in 2022: Albert Cha, Lars Holtug, Rafaèle Tordjman	Management	For	For
3.	Authorisation of the chairman of the meeting: The Board of Directors proposes that Rafaèle Tordjman is elected.	Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Special
Ticker Symbol	ASND	Meeting Date	18-Nov-2021
Record Date	21-Oct-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Elect Lars Lüthjohan Jensen as chairman of the meeting	Management	For	For
2.	Elect Rafaèle Tordjman to the board	Management	For	For
3.	Authorize the chairman of the meeting to register Rafaèle Tordjman with the Danish Business Authority, if elected	Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	30-May-2022
Record Date	22-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company's Activities during the Past Year	Management	For	For
3.	Approval of Audited Annual Report with Auditor's Statement and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5a.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Albert Cha	Management	For	For
5b.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Rafaèle Tordjman	Management	For	For
5c.	Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Lars Holtug	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7a.	The Board of Directors proposes to amend the Articles of Association by renewing the authorisation to the Board of Directors to obtain loan against issuance of convertible bonds which gives the right to subscribe up to nominal DKK 9,000,000 new shares in the Company.	Management	For	For
7b.	The Board of Directors proposes to amend the Articles of Association by adoption of an authorization to the Board of Directors to issue up to nominal 1,000,000 warrants to employees, advisors, consultants and executive management. The exercise price shall be equal to at least the market price at the time of grant.	Management	For	For

ASTRAZENECA PLC

Security	046353108	Meeting Type	Annual
Ticker Symbol	AZN	Meeting Date	29-Apr-2022
Record Date	07-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021	Management	For	For
2.	To confirm dividends	Management	For	For
3.	To reappoint PricewaterhouseCoopers LLP as Auditor	Management	For	For
4.	To authorise the Directors to agree the remuneration of the Auditor	Management	For	For
5A.	Re-election of Director: Leif Johansson	Management	For	For
5B.	Re-election of Director: Pascal Soriot	Management	For	For
5C.	Election of Director: Aradhana Sarin	Management	For	For
5D.	Re-election of Director: Philip Broadley	Management	For	For
5E.	Re-election of Director: Euan Ashley	Management	For	For
5F.	Re-election of Director: Michel Demaré	Management	For	For
5G.	Re-election of Director: Deborah DiSanzo	Management	For	For
5H.	Re-election of Director: Diana Layfield	Management	For	For
5I.	Re-election of Director: Sheri McCoy	Management	For	For
5J.	Re-election of Director: Tony Mok	Management	For	For
5K.	Re-election of Director: Nazneen Rahman	Management	For	For
5L.	Election of Director: Andreas Rummelt	Management	For	For
5M.	Re-election of Director: Marcus Wallenberg	Management	For	For
6.	To approve the Annual Report on Remuneration for the year ended 31 December 2021	Management	For	For
7.	To authorise limited political donations	Management	For	For
8.	To authorise the Directors to allot shares	Management	For	For
9.	To authorise the Directors to disapply pre-emption rights (Special Resolution)	Management	For	For
10.	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution)	Management	For	For
11.	To authorise the Company to purchase its own shares (Special Resolution)	Management	For	For
12.	To reduce the notice period for general meetings (Special Resolution)	Management	For	For
13.	To extend the AstraZenca PLC 2012 Savings Related Share Option Scheme	Management	For	For

AURINIA PHARMACEUTICALS, INC.

Security	05156V102	Meeting Type	Annual
Ticker Symbol	AUPH	Meeting Date	17-May-2022
Record Date	14-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1.	Dr. George M. Milne		For	For
	2.	Mr. Peter Greenleaf		For	For
	3.	Dr. David R.W. Jayne		For	For
	4.	Mr. Joseph P. Hagan		For	For
	5.	Dr. Daniel G. Billen		For	For
	6.	Mr. R. H. MacKay-Dunn		For	For
	7.	Ms. Jill Leversage		For	For
	8.	Mr. Timothy P. Walbert		For	For
	9.	Dr. Brinda Balakrishnan		For	For
2	Appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the 2023 annual general meeting of shareholders or until a successor is appointed.		Management	For	For
3	To approve, on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation set forth in the Company's Proxy Statement/Circular.		Management	For	For

AVIDITY BIOSCIENCES, INC.

Security	05370A108	Meeting Type	Annual
Ticker Symbol	RNA	Meeting Date	15-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to serve for a three-year term expiring at the 2025 Annual Meeting: Tamar Thompson	Management	For	For
1.2	Election of Class II Director to serve for a three-year term expiring at the 2025 Annual Meeting: Eric Mosbrooker	Management	For	For
2.	To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For
4.	To consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended, should occur every one, two or three years.	Management	1 Year	For

BEAM THERAPEUTIC,S INC.

Security	07373V105	Meeting Type	Annual
Ticker Symbol	BEAM	Meeting Date	08-Jun-2022
Record Date	11-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director for a three-year term ending at the 2025 Annual Meeting: Mark Fishman, M.D.	Management	For	For
1b.	Election of Class II Director for a three-year term ending at the 2025 Annual Meeting: Carole Ho, M.D.	Management	For	For
1c.	Election of Class II Director for a three-year term ending at the 2025 Annual Meeting: Kathleen Walsh	Management	For	For
2.	Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.	Management	For	For
3.	Approve, on an advisory basis, the compensation of our named executive officers.	Management	For	For
4.	Indicate, on an advisory basis, the preferred frequency of advisory votes on executive compensation.	Management	1 Year	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	22-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Anthony C. Hooper be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
2.	THAT Ranjeev Krishana be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
3.	THAT Xiaodong Wang be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT Qingqing Yi be and is hereby re-elected to serve as a Class III director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
5.	THAT Margaret Dugan be and is hereby re-elected to serve as a Class I director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.	Management	For	For
6.	THAT Alessandro Riva be and is hereby re-elected to serve as a Class I director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
7.	THAT the selection of Ernst & Young LLP, Ernst & Young Hua Ming LLP and Ernst & Young as the Company's reporting accounting firms for the fiscal year ending December 31, 2022 be and is hereby approved, ratified and confirmed.	Management	For	For
8.	THAT the granting of a share issue mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	For	For
9.	THAT the granting of a share repurchase mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	For	For
10.	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	For	For
11.	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	For	For
12.	THAT the grant of an option to acquire shares to Amgen to allow ...(due to space limits, see proxy material for full proposal).	Management	For	For
13.	THAT the grant of restricted share units ("RSUs") with a grant ...(due to space limits, see proxy material for full proposal).	Management	For	For
14.	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	For	For
15.	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	For	For
16.	THAT the Amendment No. 2 to the 2016 Plan to increase the number ...(due to space limits, see proxy material for full proposal).	Management	For	For
17.	THAT, on a non-binding, advisory basis, the compensation of the ...(due to space limits, see proxy material for full proposal).	Management	For	For
18.	THAT the adjournment of the Annual Meeting by the chairman, if ...(due to space limits, see proxy material for full proposal).	Management	For	For

BELLICUM PHARMACEUTICALS, INC.

Security	079481404	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	15-Jun-2022
Record Date	19-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Judith Klimovsky, M.D.		For	For
2.	To approve an amendment to the Company's 2019 Equity Incentive Plan to, among other things, increase the number of shares of common stock authorized for issuance thereunder by 2,250,000 shares.		Management	For	For
3.	To ratify the Audit Committee's selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.		Management	For	For
4.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.		Management	For	For

BICYCLE THERAPEUTICS PLC

Security	088786108	Meeting Type	Annual
Ticker Symbol	BCYC	Meeting Date	27-Jun-2022
Record Date	22-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect as a director Pierre Legault, who retires in accordance with the Articles of Association.	Management	For	For
2.	To re-elect as a director Richard Kender, who retires in accordance with the Articles of Association.	Management	For	For
3.	To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.	Management	For	For
4.	To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For
5.	To approve the amendment of the Bicycle Therapeutics plc 2020 Equity Incentive Plan to increase the number of shares available for issuance under the plan.	Management	For	For
6.	To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2022.	Management	For	For
7.	To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.	Management	For	For
8.	To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2022.	Management	For	For
9.	To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2021.	Management	For	For
10.	To approve the directors' remuneration report for the year ended December 31, 2021, which is set forth as Annex A to the proxy statement.	Management	For	For

BIOCRYST PHARMACEUTICALS, INC.

Security	09058V103	Meeting Type	Annual
Ticker Symbol	BCRX	Meeting Date	07-Jun-2022
Record Date	11-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Stephen J. Aselage		For	For
	2.	Steven K.Galson,M.D,MPH		For	For
	3.	Kenneth B. Lee, Jr.		For	For
	4.	Alan G. Levin		For	For
2.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2022.		Management	For	For
3.	To approve, on an advisory basis, the Company's executive compensation.		Management	For	For
4.	To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 8,000,000 shares.		Management	For	For

BIOGEN, INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	15-Jun-2022
Record Date	21-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Alexander J. Denner	Management	For	For
1b.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Caroline D. Dorsa	Management	For	For
1c.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Maria C. Freire	Management	For	For
1d.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: William A. Hawkins	Management	For	For
1e.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: William D. Jones	Management	For	For
1f.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Jesus B. Mantas	Management	For	For
1g.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Richard C. Mulligan	Management	For	For
1h.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Stelios Papadopoulos	Management	For	For
1i.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Eric K. Rowinsky	Management	For	For
1j.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Stephen A. Sherwin	Management	For	For
1k.	Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

Security	G11196105	Meeting Type	Annual
Ticker Symbol	BHVN	Meeting Date	28-Apr-2022
Record Date	02-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director for a term expiring at the 2025 Annual Meeting: John W. Childs	Management	For	For
1B.	Election of Director for a term expiring at the 2025 Annual Meeting: Gregory H. Bailey	Management	For	For
1C.	Election of Director for a term expiring at the 2025 Annual Meeting: Kishan Mehta	Management	For	For
2.	Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2022.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Named Executive Officers.	Management	For	For

BIOMARIN PHARMACEUTICAL, INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	24-May-2022
Record Date	28-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Mark J. Alles		For	For
	2.	Elizabeth M. Anderson		For	For
	3.	Jean-Jacques Bienaimé		For	For
	4.	Willard Dere		For	For
	5.	Elaine J. Heron		For	For
	6.	Maykin Ho		For	For
	7.	Robert J. Hombach		For	For
	8.	V. Bryan Lawlis		For	For
	9.	Richard A. Meier		For	For
	10.	David E.I. Pyott		For	For
	11.	Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2022.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.		Management	For	For

BIONTECH SE

Security	09075V102	Meeting Type	Annual
Ticker Symbol	BNTX	Meeting Date	01-Jun-2022
Record Date	27-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
2	Resolution on appropriation of balance sheet profit	Management	For	For
3	Approval of the actions of the Management Board	Management	For	For
4	Approval of the actions of the Supervisory Board	Management	For	For
5	Appointment of the Auditor for the 2022 Financial Year	Management	For	For
6	Resolution on the approval of the remuneration report	Management	For	For
7	Resolution on the Amendments to Sec. 9 para. 1 of the Articles of Association (expansion of the Supervisory Board)	Management	For	For
8.1	Election to the Supervisory Board: Prof. Dr. Anja Morawietz	Management	For	For
8.2	Election to the Supervisory Board: Prof. Dr. Rudolf Staudigl	Management	For	For
8.3	Election to the Supervisory Board: Helmut Jeggle	Management	For	For
9	Resolution on the remuneration and on the remuneration system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association	Management	For	For
10a	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Innovation GmbH as dependent company	Management	For	For
10b	Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Innovation and Services Marburg GmbH as dependent company	Management	For	For

BIOTHERYX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	24-Sep-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the amended and restated certificate of incorporation.	Management	For	For
2.	Approval of the 2021 Equity Incentive Plan.	Management	For	For

BIOTHERYX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	04-Nov-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Increase to Board Size.	Management	For	For
2.	Appointment of Director.	Management	For	For

BLACK DIAMOND THERAPEUTICS, INC.

Security	09203E105	Meeting Type	Annual
Ticker Symbol	BDTX	Meeting Date	07-Jun-2022
Record Date	13-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Ali Behbahani		For	For
	2.	Garry E. Menzel		For	For
	3.	Samarth Kulkarni		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.'s independent registered accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	21-Jun-2022
Record Date	25-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Jeffrey W. Albers		For	For
	2.	Mark Goldberg, M.D.		For	For
	3.	Nicholas Lydon, Ph.D.		For	For
2.	To approve an advisory vote on named executive officer compensation.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

CATALENT, INC.

Security	148806102	Meeting Type	Annual
Ticker Symbol	CTLT	Meeting Date	28-Oct-2021
Record Date	03-Sep-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Madhavan Balachandran	Management	For	For
1B.	Election of Director: Michael J. Barber	Management	For	For
1C.	Election of Director: J. Martin Carroll	Management	For	For
1D.	Election of Director: John Chiminski	Management	For	For
1E.	Election of Director: Rolf Classon	Management	For	For
1F.	Election of Director: Rosemary A. Crane	Management	For	For
1G.	Election of Director: John Greisch	Management	For	For
1H.	Election of Director: Christa Kreuzburg	Management	For	For
1I.	Election of Director: Gregory T. Lucier	Management	For	For
1J.	Election of Director: Donald E. Morel, Jr.	Management	For	For
1K.	Election of Director: Jack Stahl	Management	For	For
2.	Ratification of Appointment of Independent Auditor for Fiscal 2022.	Management	For	For
3.	Advisory Vote to Approve Our Executive Compensation (Say-on-Pay).	Management	For	For
4.	Advisory Vote on the Frequency of Advisory Votes in Respect of Executive Compensation.	Management	1 Year	For
5.	Amend our Certificate of Incorporation to Remove the Limitation on Calling Shareholder Special Meetings.	Management	For	For
6.	Amend our Certificate of Incorporation to Add a Federal Forum Selection Provision.	Management	For	For
7.	Amend and Restate our Certificate of Incorporation to (i) Eliminate the Supermajority Vote Requirement for Amendments and (ii) Make Non-Substantive and Conforming Changes.	Management	For	For

CEREVEL THERAPEUTICS HOLDINGS, INC.

Security	15678U128	Meeting Type	Annual
Ticker Symbol	CERE	Meeting Date	14-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to serve for a three-year term expiring at the 2025 annual meeting: Deborah Baron	Management	For	For
1.2	Election of Class II Director to serve for a three-year term expiring at the 2025 annual meeting: Doug Giordano	Management	For	For
1.3	Election of Class II Director to serve for a three-year term expiring at the 2025 annual meeting: Adam Koppel	Management	For	For
1.4	Election of Class II Director to serve for a three-year term expiring at the 2025 annual meeting: Ruth McKernan	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.	Management	For	For
3.	To approve, on a non-binding advisory basis, the frequency of future advisory votes on named executive officers' compensation.	Management	1 Year	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.	Management	For	For

CHARLES RIVER LABORATORIES INTL., INC.

Security	159864107	Meeting Type	Annual
Ticker Symbol	CRL	Meeting Date	10-May-2022
Record Date	21-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: James C. Foster	Management	For	For
1B.	Election of Director: Nancy C. Andrews	Management	For	For
1C.	Election of Director: Robert Bertolini	Management	For	For
1D.	Election of Director: Deborah T. Kochevar	Management	For	For
1E.	Election of Director: George Llado, Sr.	Management	For	For
1F.	Election of Director: Martin W. MacKay	Management	For	For
1G.	Election of Director: George E. Massaro	Management	For	For
1H.	Election of Director: C. Richard Reese	Management	For	For
1I.	Election of Director: Richard F. Wallman	Management	For	For
1J.	Election of Director: Virginia M. Wilson	Management	For	For
2.	Advisory approval of 2021 Executive Compensation	Management	For	For
3.	Ratification of PricewaterhouseCoopers LLC as independent registered accounting public firm for 2022	Management	For	For

CHEMOCENTRYX, INC.

Security	16383L106	Meeting Type	Annual
Ticker Symbol	CCXI	Meeting Date	26-May-2022
Record Date	31-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Geoffrey M. Parker	Management	For	For
1B.	Election of Director: James L. Tyree	Management	For	For
1C.	Election of Director: David Wheadon, M.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2022.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure of the Securities and Exchange Commission.	Management	For	For

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Security	21833P103	Meeting Type	Annual
Ticker Symbol	CRBP	Meeting Date	18-May-2022
Record Date	24-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Yuval Cohen		For	For
	2.	Alan Holmer		For	For
	3.	Avery W. Catlin		For	For
	4.	Rachelle Jacques		For	For
	5.	John Jenkins		For	For
	6.	Peter Salzmann		For	For
2.	Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.		Management	For	For
3.	Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.		Management	For	For

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	09-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the Swiss statutory annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2021.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of Rodger Novak, M.D., as member and Chairman	Management	For	For
4b.	Re-election of Samarth Kulkami, Ph.D. as the member to the Board of Director.	Management	For	For
4c.	Re-election of Ali Behbahani, M.D. as the member to the Board of Director.	Management	For	For
4d.	Re-election of Bradley Bolzon, Ph.D. as the member to the Board of Director.	Management	For	For
4e.	Re-election of H. Edward Fleming, Jr. M.D. as the member to the Board of Director.	Management	For	For
4f.	Re-election of Simeon J. George, M.D. as the member to the Board of Director.	Management	For	For
4g.	Re-election of John T. Greene as the member to the Board of Director.	Management	For	For
4h.	Re-election of Katherine A. High, M.D. as the member to the Board of Director.	Management	For	For
4i.	Re-election of Douglas A. Treco, Ph.D. as the member to the Board of Director.	Management	For	For
4j.	Election of Maria Fardis, Ph.D. as the member to the Board of Director.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Ali Behbahani, M.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: John T. Greene	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2022 Annual General Meeting to the 2023 annual general meeting of shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2022 Annual General Meeting to the 2023 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2022 to June 30, 2023.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2022.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2022 Annual General Meeting to the 2023 annual general meeting of shareholders.	Management	For	For
7.	Non-binding advisory vote to approve the compensation paid to the Company's named executive officers under U.S. securities law requirements.	Management	For	For
8.	Non-binding advisory vote on the frequency of future shareholder advisory votes on the compensation paid to the Company's named executive officers under U.S. securities law requirements.	Management	3 Years	For
9.	The approval of increasing the maximum size of the Board of Directors.	Management	For	For
10.	The approval of an adjustment of the maximum number of authorized share capital and extending the date by which the Board of Directors may increase the share capital.	Management	For	For
11.	The approval of an adjustment of the conditional share capital for the conversion of bonds and similar debt instruments.	Management	For	For
12.	The approval of an increase in the conditional share capital for employee equity plans.	Management	For	For
13.	The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.	Management	For	For
14.	The re-election of the independent voting rights representative.	Management	For	For
15.	The re-election of the auditors.	Management	For	For
16.	The transaction of any other business that may properly come before the 2022 Annual General Meeting or any adjournment or postponement thereof.	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	20-Oct-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment To Certificate of Incorporation.	Management	For	For
2.	Series A Preferred Stock Extension Financing.	Management	For	For
3.	Increase to Board Size; Appointment of New Series A Director.	Management	For	For
4.	Indemnification Agreement.	Management	For	For
5.	Waiver of Preemptive Rights.	Management	For	For
6.	General Authority and Ratification.	Management	For	For

CYTOKINETICS, INCORPORATED

Security	23282W605	Meeting Type	Annual
Ticker Symbol	CYTK	Meeting Date	10-May-2022
Record Date	21-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to serve for a three-year term: Muna Bhanji	Management	For	For
1.2	Election of Class III Director to serve for a three-year term: Santo J. Costa, Esq.	Management	For	For
1.3	Election of Class III Director to serve for a three-year term: John T. Henderson, M.B., Ch.B.	Management	For	For
1.4	Election of Class III Director to serve for a three-year term: B. Lynne Parshall, Esq.	Management	For	For
2.	To approve the amendment and restatement of the Amended and Restated 2004 Equity Incentive Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2004 Equity Incentive Plan by an additional 5,998,000 shares of common stock.	Management	For	For
3.	To ratify the Audit Committee of our Board of Directors' selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
4.	To approve, on an advisory basis, the compensation of the named executive officers, as identified and disclosed in the Cytokinetics, Incorporated Proxy Statement for the 2022 Annual Meeting of Stockholders.	Management	For	For

DENALI THERAPEUTICS INC.

Security	24823R105	Meeting Type	Annual
Ticker Symbol	DNLI	Meeting Date	02-Jun-2022
Record Date	11-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Vicki Sato, Ph.D.		For	For
	2.	Erik Harris		For	For
	3.	Peter Klein		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.		Management	For	For
3.	Advisory vote on executive compensation.		Management	For	For

DESIGN THERAPEUTICS INC

Security	25056L103	Meeting Type	Annual
Ticker Symbol	DSGN	Meeting Date	15-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to serve for three-year terms until the 2025 Annual Meeting: Heather Berger, Ph.D. (formerly Heather Behanna, Ph.D.)	Management	For	For
1.2	Election of Class I Director to serve for three-year terms until the 2025 Annual Meeting: Rodney Lappe, Ph.D.	Management	For	For
1.3	Election of Class I Director to serve for three-year terms until the 2025 Annual Meeting: John Schmid	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	09-Jul-2021
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of the IPO of the Company and waiver of any rights under the Shareholders’ Agreement in connection with the IPO		Management		For		For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	06-Jan-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Share capital increase by contribution in cash, of a nominal amount of 10,528.04 through the issuance of 263,201 new ordinary shares labelled C shares.	Management	For	For
2.	Cancellation of the preferential subscription right of the shareholders in favor of a named beneficiary.	Management	For	For
3.	Overall revision of the Company's by-laws, subject to the condition precedent of the completion of the capital increase covered by the first and second resolutions.	Management	For	For
4.	Delegation of authority to the Board of Directors to decide to increase the share capital with cancellation of the preferential subscription right, by a maximum nominal amount of 26,506 euros though the issuance of a maximum of 662,650 ABSA C with a nominal value of four euro cents (€0.04) each.	Management	For	For
5.	Cancellation of the preferential subscription right of the shareholders in favor of a named beneficiary.	Management	For	For
6.	Delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximum number of 642,789 shares outstanding.	Management	For	For
7.	Delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximum number of 642,789 BSA2022.	Management	For	For
8.	Cancellation of the shareholders’ preferential subscription right with respect to the BSA2022 in favor of determined categories of beneficiaries.	Management	For	For
9.	Delegation of competence granted to the Board of Directors to decide the issuance and allocation of 642,789 AGA2022.	Management	For	For
10.	Delegation of authority to the Board of Directors to increase the share capital by way of the issue of shares of the Company to participants in a company savings plan (plan d’épargne d’entreprise) established in accordance with articles L. 3332-1 et seq. of the French Labour Code.	Management	For	For
11.	Power to carry out formalities.	Management	For	For

DYNACURE

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	23-Jun-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the annual financial statements for the fiscal year ended December 31, 2021 and discharge of the Chairman of the Board of Directors, the Chief Executive Officer, the Directors and the statutory auditors for the performance of their duties during the past fiscal year.	Management	For	For
2.	Allocation of the result for the fiscal year ended December 31, 2021.	Management	For	For
3.	Review of the agreements referred to in Articles L. 225-38 et seq. of the French Commercial Code.	Management	For	For
4.	Renewal of the terms of office of Bpifrance Investissement, Kurma Partners and Chris Mirabelli as directors.	Management	For	For
5.	Renewal of the terms of office of Ellen Hukkelhoven as observer.	Management	For	For
6.	Powers to carry out formalities.	Management	For	For

EDGEWISE THERAPEUTICS, INC.

Security	28036F105	Meeting Type	Annual
Ticker Symbol	EWTX	Meeting Date	23-Jun-2022
Record Date	27-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Kenneth Harrison, Ph.D.		For	For
	2.	Alan Russell, Ph.D.		For	For
2.	Ratify the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

ENDEAVOR BIOMEDICINES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	03-Mar-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment to Amended and Restated Certificate of Incorporation.	Management	For	For
2.	Amendment to Series B Preferred Stock Purchase Agreement.	Management	For	For
3.	General Authority and Ratification.	Management	For	For

ENDO INTERNATIONAL PLC

Security	G30401106	Meeting Type	Annual
Ticker Symbol	ENDP	Meeting Date	09-Jun-2022
Record Date	11-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Mark G. Barberio	Management	For	For
1b.	Election of Director: Jennifer M. Chao	Management	For	For
1c.	Election of Director: Blaise Coleman	Management	For	For
1d.	Election of Director: Shane M. Cooke	Management	For	For
1e.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1f.	Election of Director: Michael Hyatt	Management	For	For
1g.	Election of Director: William P. Montague	Management	For	For
1h.	Election of Director: M. Christine Smith, Ph.D.	Management	For	For
2.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
3.	To renew the Board's existing authority to issue shares under Irish law.	Management	For	For
4.	To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For
5.	To approve the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022 and to authorize the Board of Directors, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm's remuneration.	Management	For	For

FATE THERAPEUTICS, INC.

Security	31189P102	Meeting Type	Annual
Ticker Symbol	FATE	Meeting Date	09-Jun-2022
Record Date	12-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Timothy P. Coughlin		For	For
	2.	J. Scott Wolchko		For	For
	3.	Dr. Shefali Agarwal		For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.		Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.		Management	For	For
4.	To approve the Fate Therapeutics, Inc. 2022 Stock Option and Incentive Plan.		Management	For	For

FULCRUM THERAPEUTICS, INC.

Security	359616109	Meeting Type	Annual
Ticker Symbol	FULC	Meeting Date	08-Jun-2022
Record Date	11-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to serve for a 3-year term expiring at the 2025 Annual meeting: Kate Haviland	Management	For	For
1.2	Election of Class III Director to serve for a 3-year term expiring at the 2025 Annual meeting: Katina Dorton	Management	For	For
1.3	Election of Class III Director to serve for a 3-year term expiring at the 2025 Annual meeting: Robert Gould	Management	For	For
2.	To ratify the appointment of Ernst & Young as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2022.	Management	For	For

G1 THERAPEUTICS, INC.

Security	3621LQ109	Meeting Type	Annual
Ticker Symbol	GTHX	Meeting Date	23-Jun-2022
Record Date	25-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director: Alicia Secor	Management	For	For
2.	An advisory (non-binding) vote to approve executive compensation	Management	For	For
3.	The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2022	Management	For	For

GALERA THERAPEUTICS, INC.

Security	36338D108	Meeting Type	Annual
Ticker Symbol	GRTX	Meeting Date	15-Jun-2022
Record Date	22-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Emmett Cunningham		For	For
	2.	J. Mel Sorensen		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

GAMIDA CELL LTD.

Security	M47364100	Meeting Type	Annual
Ticker Symbol	GMDA	Meeting Date	17-Nov-2021
Record Date	18-Oct-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director to hold office until the annual general meeting to be held in 2024: Mr. Robert I. Blum	Management	For	For
1B.	Election of Class III Director to hold office until the annual general meeting to be held in 2024: Dr. Julian Adams	Management	For	For
1C.	Election of Class III Director to hold office until the annual general meeting to be held in 2024: Mr. Ofer Gonen	Management	For	For
2.	To approve an amendment of the terms of office and employment of the Company's Chief Executive Officer (and a member of the Board), Dr. Julian Adams.	Management	For	For
3.	To approve an amendment to the indemnification agreements for directors and executives officers.	Management	For
3A.	Are you a controlling shareholder in the Company, or do you have a personal interest in the approval of Proposal No. 3? (If your interest arises solely from the fact that you hold shares in the Company, you would not be deemed to have a personal interest.) (Please note: If you do not mark either Yes or No, your shares will not be voted for Proposal No. 3.) Mark "for" = yes or "against" = no.	Management	Against
4.	To approve an amendment to the Company's 2017 Share Incentive Plan.	Management	For	For
5.	To approve amendments to the Company's amended and restated articles of association.	Management	For	For
6.	To approve an amendment to the compensation terms for directors of the Company.	Management	For	For
7.	To approve the re-appointment of Kost, Forer, Gabbay & Kasierer, a member firm of Ernst & Young Global, as the Company's independent auditors for the fiscal year ending December 31, 2021, and its service until the annual general meeting of shareholders to be held in 2022.	Management	For	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	04-May-2022
Record Date	15-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1B.	Election of Director: Jeffrey A. Bluestone, Ph.D.	Management	For	For
1C.	Election of Director: Sandra J. Horning, M.D.	Management	For	For
1D.	Election of Director: Kelly A. Kramer	Management	For	For
1E.	Election of Director: Kevin E. Lofton	Management	For	For
1F.	Election of Director: Harish Manwani	Management	For	For
1G.	Election of Director: Daniel P. O'Day	Management	For	For
1H.	Election of Director: Javier J. Rodriguez	Management	For	For
1I.	Election of Director: Anthony Welters	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To approve the Gilead Sciences, Inc. 2022 Equity Incentive Plan.	Management	For	For
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.	Shareholder	Against	For
6.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board include one member from Gilead's non-management employees.	Shareholder	Against	For
7.	To vote on a stockholder proposal, if properly presented at the meeting, requesting a 10% threshold to call a special stockholder meeting.	Shareholder	Against	For
8.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board publish a third- party review of Gilead's lobbying activities.	Shareholder	Against	For
9.	To vote on a stockholder proposal, if properly presented at the meeting, requesting a Board report on oversight of risks related to anticompetitive practices.	Shareholder	Against	For

GUARDANT HEALTH, INC.

Security	40131M109	Meeting Type	Annual
Ticker Symbol	GH	Meeting Date	15-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class I Director: Vijaya Gadde	Management	For	For
1B.	Election of Class I Director: Myrtle Potter	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2022.	Management	For	For
3.	Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.	Management	For	For

HARPOON THERAPEUTICS, INC.

Security	41358P106	Meeting Type	Annual
Ticker Symbol	HARP	Meeting Date	22-Jun-2022
Record Date	25-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Julie Eastland		For	For
	2.	Scott Myers		For	For
2.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

HELIX ACQUISITION CORP

Security	G4444C102	Meeting Type	Special
Ticker Symbol	HLXA	Meeting Date	31-Mar-2022
Record Date	07-Jan-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A proposal, as an ordinary resolution, to approve the business combination agreement, dated as of October 4, 2021, by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation ("MoonLake"), certain securityholders of MoonLake (the "ML Parties"),and the other parties thereto,a copy of which is attached to the accompanying proxy statement as Annex A-1, and approve the transactions contemplated by the Business Combination Agreement (the "Business Combination") and other ...(due to space limits, see proxy material for full proposal).	Management	For	For
2A.	Binding Organizational Documents Proposal A: a proposal, as an ordinary resolution, to approve the change in authorized share capital of Helix, from US$55,500 divided into 500,000,000 Class A Ordinary Shares, 50,000,000 Class B Ordinary Shares, and 5,000,000 preference shares, to US$65,500 divided into 500,000,000 Class A Ordinary Shares, 50,000,000 Class B Ordinary Shares,100,000,000 Class C Ordinary Shares, and 5,000,000 preference shares by the creation of an additional 100,000,000 ...(due to space limits, see proxy material for full proposal).	Management	For	For
2B.	Binding Organizational Documents Proposal B: a proposal, as a special resolution, to approve the change in Helix's name, from "Helix Acquisition Corp." to "MoonLake Immunotherapeutics".	Management	For	For

2C.	Binding Organizational Documents Proposal C: a proposal, as special resolution, to approve the adoption of the second amended and restated memorandum and articles of association of the Company (the "Proposed MAA"), a copy of which is attached to the accompanying proxy statement as Annex B.	Management	For	For
3A.	Advisory Organizational Documents Proposal A: assuming Binding Organizational Documents Proposal A is approved, a proposal to approve an amendment to the Existing MAA to provide for an increase in the authorized share capital from US$55,500 divided into 500,000,000 Class A Ordinary Shares of a par value of US$0.0001 each, 50,000,000 Class B Ordinary Shares of a par value of US$0.0001 each and 5,000,000 preference shares of a par value of US$0.0001 each to US$65,500 divided into 500,000,000 ...(due to space limits, see proxy material for full proposal).	Management	For	For
3B.	Advisory Organizational Documents Proposal B: assuming Binding Organizational Documents Proposal A is approved, a proposal to approve an amendment to the Existing MAA to provide (i) for the rights attaching to Class A Ordinary Shares and Class C Ordinary Shares, (ii) that Class C Ordinary Shares may be transferred only as set out in the amended and restated shareholders' agreement to be entered by Helix, MoonLake and each ML Party at the Closing (the "A&R Shareholders' Agreement")to be in effect ...(due to space limits, see proxy material for full proposal).	Management	For	For
3C.	Advisory Organizational Documents Proposal C: a proposal to require the consent of a class of shares, voting separately, for any variation of the rights of such class instead of the board of directors' ability to vary class rights without consent from shareholders of a class where the board of directors considered the variation would not have a material adverse effect on such rights.	Management	For	For
3D.	Advisory Organizational Documents Proposal D: a proposal to remove the ability of the board of directors to remove one of their members for cause.	Management	For	For
3E.	Advisory Organizational Documents Proposal E: a proposal for an extended notice period for shareholders to nominate a director without a timely public announcement.	Management	For	For

3F.	Advisory Organizational Documents Proposal F: a proposal for restrictions on the ability of non-employee directors to pursue certain business opportunities wherein the Company retains its interest in any opportunity offered to any non-employee director if such opportunity is expressly offered to such non-employee director solely in his or her capacity as a director.	Management	For	For
3G.	Advisory Organizational Documents Proposal G: a proposal for the elimination of the minimum shareholder requirement in general meeting proposals and director nomination provisions.	Management	For	For
3H.	Advisory Organizational Documents Proposal H: a proposal for certain additional changes, including, among other things (i) removing terms providing for the automatic conversion of Class B Ordinary Shares to Class A Ordinary Shares in connection with consummation of an initial business combination; (ii) removing shareholder redemption provisions; (iii) removing the limitation on paying cash remuneration to directors prior to the consummation of an initial business combination iv) removing the ...(due to space limits, see proxy material for full proposal).	Management	For	For
4.	A proposal, as an ordinary resolution, to approve, for the purpose of complying with the applicable Nasdaq listing rules, (i) the issuance of Class A Ordinary Shares to certain of the ML Parties (the "BVF Shareholders") and Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders), including the Class A Ordinary Shares issuable upon the exchange of MoonLake Common Shares and simultaneous surrender of Class C Ordinary Sharesby such ML Parties, pursuant to the terms of the Business ...(due to space limits, see proxy material for full proposal).	Management	For	For
5.	A proposal, as an ordinary resolution, to approve the MoonLake Immunotherapeutics 2022 Equity Incentive Plan, a copy of which is attached to the accompanying proxy statement as Annex C (we refer to this proposal as the "Incentive Plan Proposal")	Management	For	For
6.	A proposal, as an ordinary resolution, to approve the adjournment of the extraordinary general meeting to a later date or dates, (A) to the extent necessary to ensure that any required supplement or amendment to the proxy statement is provided to Helix's shareholders; (B) if, as of the time for which the extraordinary general meeting is originally scheduled, there are insufficient ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to ...(due to space limits, see proxy material for full proposal).	Management	For	For

HORIZON THERAPEUTICS PLC

Security	G46188101	Meeting Type	Annual
Ticker Symbol	HZNP	Meeting Date	28-Apr-2022
Record Date	24-Feb-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director: Michael Grey	Management	For	For
1B.	Election of Class II Director: Jeff Himawan, Ph.D.	Management	For	For
1C.	Election of Class II Director: Susan Mahony, Ph.D.	Management	For	For
2.	Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022 and authorization of the Audit Committee to determine the auditors' remuneration.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.	Management	For	For
4.	Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.	Management	For	For
5.	Approval of the Amended and Restated 2020 Equity Incentive Plan.	Management	For	For

HOTSPOT THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Nov-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Fourth Amended and Restated Certificate of Incorporation	Management	For	For
2.	Amendment to 2017 Stock Option and Grant Plan	Management	For	For
3.	General Resolutions	Management	For	For

HOTSPOT THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Nov-2021
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Waiver of Right of First Offer.		Management		For		For

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	11-May-2022
Record Date	14-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director (Proposal One): Jonathan W. Ayers	Management	For	For
1B.	Election of Director (Proposal One): Stuart M. Essig, PhD	Management	For	For
1C.	Election of Director (Proposal One): Jonathan J. Mazelsky	Management	For	For
1D.	Election of Director (Proposal One): M. Anne Szostak	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).	Management	For	For
3.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).	Management	For	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Annual
Ticker Symbol	ILMN	Meeting Date	26-May-2022
Record Date	31-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Frances Arnold, Ph.D.	Management	For	For
1B.	Election of Director: Francis A. deSouza	Management	For	For
1C.	Election of Director: Caroline D. Dorsa	Management	For	For
1D.	Election of Director: Robert S. Epstein, M.D.	Management	For	For
1E.	Election of Director: Scott Gottlieb, M.D.	Management	For	For
1F.	Election of Director: Gary S. Guthart, Ph.D.	Management	For	For
1G.	Election of Director: Philip W. Schiller	Management	For	For
1H.	Election of Director: Susan E. Siegel	Management	For	For
1I.	Election of Director: John W. Thompson	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1, 2023.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, a stockholder proposal regarding the right of stockholders to call special meetings.	Shareholder	Against	For
5.	To approve an amendment to our Amended and Restated Certificate of Incorporation to permit stockholders to call special meetings.	Management	For	For

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	14-Jun-2022
Record Date	18-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Caroline Dorsa		For	For
	2.	G. Keresty, PhD M.P.H.		For	For
	3.	John M. Leonard, M.D.		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For
3.	Approve, on a non-binding advisory basis, the compensation of the named executive officers.		Management	For	For

INTERCEPT PHARMACEUTICALS, INC.

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	25-May-2022
Record Date	06-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve until the 2023 Annual Meeting: Paolo Fundarò	Management	For	For
1b.	Election of Director to serve until the 2023 Annual Meeting: Jerome Durso	Management	For	For
1c.	Election of Director to serve until the 2023 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D.	Management	For	For
1d.	Election of Director to serve until the 2023 Annual Meeting: Luca Benatti, Ph.D.	Management	For	For
1e.	Election of Director to serve until the 2023 Annual Meeting: Daniel Bradbury	Management	For	For
1f.	Election of Director to serve until the 2023 Annual Meeting: Keith Gottesdiener, M.D.	Management	For	For
1g.	Election of Director to serve until the 2023 Annual Meeting: Nancy Miller-Rich	Management	For	For
1h.	Election of Director to serve until the 2023 Annual Meeting: Mark Pruzanski, M.D.	Management	For	For
1i.	Election of Director to serve until the 2023 Annual Meeting: Dagmar Rosa-Bjorkeson	Management	For	For
1j.	Election of Director to serve until the 2023 Annual Meeting: Gino Santini	Management	For	For
1k.	Election of Director to serve until the 2023 Annual Meeting: Glenn Sblendorio	Management	For	For
2.	FOR the approval of the Company's Amended and Restated Equity Incentive Plan.	Management	For	For
3.	FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
4.	FOR the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.	Management	For	For

INTRA-CELLULAR THERAPIES, INC.

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	09-Jun-2022
Record Date	19-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director to serve a three-year term expiring in 2025: Sharon Mates, Ph.D.	Management	For	For
1.2	Election of Director to serve a three-year term expiring in 2025: Rory B. Riggs	Management	For	For
1.3	Election of Director to serve a three-year term expiring in 2025: Robert L. Van Nostrand	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.	Management	For	For
3.	To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For
4.	To approve by an advisory vote the frequency of holding an advisory vote on the compensation of the Company's named executive officers.	Management	1 Year	For

INVETX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	29-Mar-2022
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Election of Director		Management		For		For

INVETX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	29-Mar-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amended and Restated Certificate of Incorporation	Management	For	For
2.	Amended and Restated 2020 Equity Incentive Plan	Management	For	For
3.	Amendment to Bylaws	Management	For	For
4.	Sale and Issuance of Series B Preferred Stock	Management	For	For
5.	Protective Provision Consent	Management	For	For
6.	Waiver of Participation Rights	Management	For	For
7.	Ratification of Series B Financing	Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	02-Jun-2022
Record Date	05-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Allene M. Diaz		For	For
	2.	Michael Hayden		For	For
	3.	Joseph Klein, III		For	For
	4.	Joseph Loscalzo		For	For
2.	To approve, by non-binding vote, executive compensation.		Management	For	For
3.	Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2022 fiscal year.		Management	For	For

ITEOS THERAPEUTICS, INC.

Security	46565G104	Meeting Type	Annual
Ticker Symbol	ITOS	Meeting Date	09-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to serve until the 2025 Annual Meeting: Aaron Davis	Management	For	For
1.2	Election of Class II Director to serve until the 2025 Annual Meeting: Ann D. Rhoads	Management	For	For
1.3	Election of Class II Director to serve until the 2025 Annual Meeting: Matthew Roden, Ph.D.	Management	For	For
1.4	Election of Class II Director to serve until the 2025 Annual Meeting: Tony Ho, M.D.	Management	For	For
2.	Approval of Amended and Restated 2020 Stock Option and Incentive Plan	Management	For	For
3.	Ratification of the selection of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public accounting firm	Management	For	For

JAZZ PHARMACEUTICALS PLC

Security	G50871105	Meeting Type	Special
Ticker Symbol	JAZZ	Meeting Date	23-Sep-2021
Record Date	19-Aug-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To grant the board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply.	Management	For	For
2.	To approve any motion to adjourn the extraordinary general meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the extraordinary general meeting to approve Proposal 1.	Management	For	For

KALVISTA PHARMACEUTICALS, INC.

Security	483497103	Meeting Type	Annual
Ticker Symbol	KALV	Meeting Date	30-Sep-2021
Record Date	10-Aug-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director until the 2024 annual meeting: ALBERT CHA	Management	For	For
1B.	Election of Class III Director until the 2024 annual meeting: MARTIN EDWARDS	Management	For	For
1C.	Election of Class III Director until the 2024 annual meeting: NANCY STUART	Management	For	For
2.	The ratification of the selection, by the audit committee of our board, of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending April 30, 2022.	Management	For	For
3.	Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.	Management	For	For

KARUNA THERAPEUTICS, INC.

Security	48576A100	Meeting Type	Annual
Ticker Symbol	KRTX	Meeting Date	15-Jun-2022
Record Date	18-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Steven Paul, M.D.	Management	For	For
1b.	Election of Class III Director: Atul Pande, M.D.	Management	For	For
1c.	Election of Class III Director: Denice Torres	Management	For	For
2.	To approve, on an advisory, non-binding basis, the compensation paid to our named executive officers.	Management	For	For
3.	To approve, on an advisory, non-binding basis, the frequency of future votes on the compensation of our named executive officers.	Management	1 Year	For
4.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For

MEDPACE HOLDINGS, INC.

Security	58506Q109	Meeting Type	Annual
Ticker Symbol	MEDP	Meeting Date	20-May-2022
Record Date	24-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	August J. Troendle		For	For
	2.	Ashley M. Keating		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2022 Annual Meeting.		Management	For	For

MEREO BIOPHARMA GROUP PLC

Security	589492107	Meeting Type	Annual
Ticker Symbol	MREO	Meeting Date	16-May-2022
Record Date	01-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
O1.	That the annual report and accounts for the financial year ended 31 December 2021, together with the directors' report and independent auditor's report thereon, be received and adopted.	Management	For	For
O2.	That BDO LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next AGM at which the Company's annual report and accounts are presented.	Management	For	For
O3.	That the directors of the Company be authorised to determine BDO LLP's remuneration.	Management	For	For
O4.	That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the financial year ended 31 December 2021, be approved.	Management	For	For
O5.	That Anne Hyland be re-appointed as a director of the Company.	Management	For	For
O6.	That Dr. Pierre Jacquet be re-appointed as a director of the Company.	Management	For	For
O7.	That Dr. Deepika Pakianathan be re-appointed as a director of the Company.	Management	For	For
O8.	That Michael Wyzga be re-appointed as a director of the Company.	Management	For	For
S9.	That the new articles of association of the Company produced to the meeting and initialed by the Chairman of the meeting for the purposes of identification be adopted as the articles of association of the Company, in substitution for, and to the exclusion of, its existing articles of association.	Management	For	For

MERUS N.V.

Security	N5749R100	Meeting Type	Annual
Ticker Symbol	MRUS	Meeting Date	31-May-2022
Record Date	03-May-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Adoption of Merus N.V.'s Dutch statutory annual accounts in the English language for the financial year 2021.	Management	For	For
2.	Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2022 for purposes of Dutch law.	Management	For	For
3.	Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties.	Management	For	For
4.	Re-appointment of Len Kanavy as non-executive director.	Management	For	For
5.	Granting authorization to Merus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital.	Management	For	For
6.	Approval of the amendment of the Non-Executive Director Compensation Program ("NED Program") to (i) increase the value of option awards granted under the NED Program to more closely align with the 50th percentile of Merus N.V.'s U.S. peer group, and (ii) increase the amount by which the grant date fair value of option awards granted under the NED Program increases annually from 3% to up to 5%. The number of shares subject to such awards will continue to be determined in accordance with the NED Program.	Management	For	For
7.	Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.	Management	For	For
8.	Approval, on an advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of Merus N.V.'s named executive officers.	Management	1 Year	For

MIRATI THERAPEUTICS, INC.

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	12-May-2022
Record Date	15-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Charles M. Baum		For	For
	2.	Bruce L.A. Carter		For	For
	3.	Julie M. Cherrington		For	For
	4.	Aaron I. Davis		For	For
	5.	Henry J. Fuchs		For	For
	6.	Faheem Hasnain		For	For
	7.	Craig Johnson		For	For
	8.	Maya Martinez-Davis		For	For
	9.	David Meek		For	For
	10.	Shalini Sharp		For	For
2.	To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.		Management	For	For
4.	To approve our 2022 Equity Incentive Plan.		Management	For	For

MODERNA, INC.

Security	60770K107	Meeting Type	Annual
Ticker Symbol	MRNA	Meeting Date	28-Apr-2022
Record Date	01-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Noubar Afeyan, Ph.D.		For	For
	2.	Stéphane Bancel		For	For
	3.	François Nader, M.D.		For	For
2.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2022.		Management	For	For
4.	To vote on a shareholder proposal relating to the feasibility of transferring intellectual property.		Shareholder	For	Against

MORPHIC HOLDING, INC.

Security	61775R105	Meeting Type	Annual
Ticker Symbol	MORF	Meeting Date	08-Jun-2022
Record Date	11-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Martin Edwards, M.D.		For	For
	2.	Nisha Nanda, Ph.D.		For	For
	3.	Praveen Tipirneni, M.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers.		Management	For	For
4.	To select, on a non-binding advisory basis, the frequency of future non-binding advisory votes on the compensation paid to the Named Executive Officers.		Management	1 Year	For
5.	To approve revised limits on awards to non-employee directors under the 2019 Equity Incentive Plan.		Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	18-May-2022
Record Date	21-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Richard F. Pops		For	For
	2	Shalini Sharp		For	For
	3	Stephen A. Sherwin M.D.		For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.		Management	For	For
3.	To approve an amendment and restatement of the Company's 2020 Equity Incentive Plan.		Management	For	For
4.	To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan.		Management	For	For
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

NKARTA, INC.

Security	65487U108	Meeting Type	Annual
Ticker Symbol	NKTX	Meeting Date	08-Jun-2022
Record Date	14-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael Dybbs, Ph.D.		For	For
	2	Simeon George, M.D. MBA		For	For
	3	Leone Patterson, M.B.A.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2022.		Management	For	For

NOVAVAX, INC.

Security	670002401	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	16-Jun-2022
Record Date	19-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director to serve for a three-year term expiring at the 2025 Annual Meeting: Rachel K. King	Management	For	For
1b.	Election of Class III Director to serve for a three-year term expiring at the 2025 Annual Meeting: James F. Young, Ph.D.	Management	For	For
2.	The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.	Management	For	For
3.	Amendment and restatement of the Second Amended and Restated Certificate of Incorporation of Novavax, Inc. to eliminate the supermajority voting provisions.	Management	For	For
4.	Amendment and restatement of the Amended and Restated By-laws of Novavax, Inc. (the "By-laws") to eliminate the supermajority voting provisions.	Management	For	For
5.	Amendment and restatement of the By-laws to permit stockholder access to proxy statement of Novavax, Inc. with respect to the nomination of directors.	Management	For	For
6.	Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of Common Stock available for issuance thereunder by 2,400,000 shares, and to limit the annual non- employee director compensation to $1.5 million and $1 million for the chairman of the board and board members, respectively.	Management	For	For
7.	Amendment and restatement of the Novavax, Inc. 2013 Employee Stock Purchase Plan ("ESPP") to increase the number of shares of Common Stock available for issuance under the ESPP by 550,000 shares, such that the number of shares available for issuance is the lesser of a) 1,100,000 shares of Common Stock increased on each anniversary of the date hereof by 5% and (b) 1,650,000 shares of Common Stock.	Management	For	For
8.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Apr-2022
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Financial Statements 2021.	Management	For	For
2.	Appropriation of Balance Sheet Results 2021.	Management	For	For
3.	Discharge of the Members of the Board and Management.	Management	For	For
4.	Re-Election of the Board of Directors:
4.1	Mr. Anthony (Tony) Rosenberg	Management	For	For
4.2	Dr. Riad Sherif	Management	For	For
4.3	Mr. Àrni Audunn Blöndal	Management	For	For
4.4	Mr. Lionel Carnot	Management	For	For
4.5	Mr. Bartosz Dzikowski	Management	For	For
4.6	Dr. Xin (Sylvia) He	Management	For	For
4.7	Dr. Robert Lorne Hopfner	Management	For	For
4.8	Ms. Yi Fei (Vanessa) Huang	Management	For	For
4.9	Dr. Henry Skinner	Management	For	For
5.	Re-Election of the Auditors PricewaterhouseCoopers SA.	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Extraordinary General Meeting
Ticker Symbol	N/A	Meeting Date	30-Nov-2021
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Ordinary share capital Increase	Management	For	For
2.	Conditional capital share increase	Management	For	For

PRAXIS PRECISION MEDICINES, INC.

Security	74006W108	Meeting Type	Annual
Ticker Symbol	PRAX	Meeting Date	26-May-2022
Record Date	28-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class II Director to serve until the 2025 Annual Meeting: Jeffrey Chodakewitz, M.D.	Management	For	For
1B.	Election of Class II Director to serve until the 2025 Annual Meeting: Merit Cudkowicz, M.D.	Management	For	For
1C.	Election of Class II Director to serve until the 2025 Annual Meeting: Stefan Vitorovic	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.	Management	For	For
4.	To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	Against

PRECISION BIOSCIENCES, INC.

Security	74019P108	Meeting Type	Annual
Ticker Symbol	DTIL	Meeting Date	10-May-2022
Record Date	15-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kevin J. Buehler		For	For
	2	Shari Lisa Piré		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2022.		Management	For	For

PRIOTHERA LTD.

Security	N/A	Meeting Type	Extraordinary General Meeting
Ticker Symbol	N/A	Meeting Date	28-Sep-2021
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Partial waiver of tranche 2 milestone condition.		Management		For		For

PROTAGONIST THERAPEUTICS, INC.

Security	74366E102	Meeting Type	Annual
Ticker Symbol	PTGX	Meeting Date	26-May-2022
Record Date	31-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Harold E. Selick, Ph.D.		For	For
	2	Bryan Giraudo		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers.		Management	For	For
3.	To recommend, by non-binding vote, the frequency of future executive compensation votes.		Management	1 Year	For
4.	To ratify the selection by the Audit Committee of the Board of Ernst & Young LLP as Protagonist Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

PYXIS ONCOLOGY, INC.

Security	747324101	Meeting Type	Annual
Ticker Symbol	PYXS	Meeting Date	13-Jun-2022
Record Date	20-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: Darren Cline	Management	For	For
2.	Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2022	Management	For	For

RALLYBIO CORPORATION

Security	75120L100	Meeting Type	Annual
Ticker Symbol	RLYB	Meeting Date	24-May-2022
Record Date	30-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: Martin W. Mackay	Management	For	For
1.2	Election of Class I Director: Kush M. Parmar	Management	For	For
1.3	Election of Class I Director: Paula Soteropoulos	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm.	Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	10-Jun-2022
Record Date	12-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Bonnie L. Bassler, Ph.D.	Management	For	For
1b.	Election of Director: Michael S. Brown, M.D.	Management	For	For
1c.	Election of Director: Leonard S. Schleifer, M.D., Ph.D.	Management	For	For
1d.	Election of Director: George D. Yancopoulos, M.D., Ph.D.	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	Proposal to approve, on an advisory basis, executive compensation.	Management	For	For

REPARE THERAPEUTICS, INC.

Security	760273102	Meeting Type	Annual
Ticker Symbol	RPTX	Meeting Date	13-May-2022
Record Date	21-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II director to hold office until the Annual Meeting of Shareholders in 2025: David Bonita, M.D.	Management	For	For
1.2	Election of Class II director to hold office until the Annual Meeting of Shareholders in 2025: Thomas Civik	Management	For	For
1.3	Election of Class II director to hold office until the Annual Meeting of Shareholders in 2025: Carol A. Schafer	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.	Management	For	For
3.	To recommend, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.	Management	1 Year	For
4.	To appoint Ernst & Young LLP as our independent registered public accounting firm (the "auditor") for the fiscal year ending December 31, 2022, and to authorize the Board of Directors to fix the auditor's remuneration.	Management	For	For

REPLIMUNE GROUP, INC.

Security	76029N106	Meeting Type	Annual
Ticker Symbol	REPL	Meeting Date	08-Sep-2021
Record Date	15-Jul-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Robert Coffin, Ph.D.		For	For
	2.	Hyam Levitsky, M.D.		For	For
	3.	Dieter Weinand		For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2022.		Management	For	For

SAREPTA THERAPEUTICS, INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	02-Jun-2022
Record Date	08-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to hold office until the 2024 Annual meeting: Kathryn Boor, Ph.D.	Management	For	For
1.2	Election of Class I Director to hold office until the 2024 Annual meeting: Michael Chambers	Management	For	For
1.3	Election of Class I Director to hold office until the 2024 Annual meeting: Douglas S. Ingram	Management	For	For
1.4	Election of Class I Director to hold office until the 2024 Annual meeting: Hans Wigzell, M.D., Ph.D.	Management	For	For
2.	To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.	Management	For	For
3.	To approve an amendment to the Company's 2018 Equity Incentive Plan (the "2018 Plan") to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 10,687,596 shares.	Management	For	For
4.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2022.	Management	For	For

SCHOLAR ROCK HOLDING CORPORATION

Security	80706P103	Meeting Type	Annual
Ticker Symbol	SRRK	Meeting Date	26-May-2022
Record Date	04-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	N. K. Mahanthappa Ph.D.		For	For
	2.	Joshua Reed		For	For
2.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

SEAGEN, INC.

Security	81181C104	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	13-May-2022
Record Date	17-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Class III Director: Ted W. Love, M.D.	Management	For	For
1B.	Election of Class III Director: Daniel G. Welch	Management	For	For
2.	Approve, on an advisory basis, the compensation of Seagen's named executive officers as disclosed in the accompanying proxy statement.	Management	For	For
3.	Ratify the appointment of PricewaterhouseCoopers LLP as Seagen's independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For

SPECTRUM PHARMACEUTICALS, INC.

Security	84763A108	Meeting Type	Annual
Ticker Symbol	SPPI	Meeting Date	21-Jun-2022
Record Date	25-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: William L. Ashton	Management	For	For
1.2	Election of Director: Brittany K. Bradrick	Management	For	For
1.3	Election of Director: Seth H.Z. Fischer	Management	For	For
1.4	Election of Director: Juhyun Lim	Management	For	For
1.5	Election of Director: Thomas J. Riga	Management	For	For
1.6	Election of Director: Jeffrey L. Vacirca	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.	Management	For	For
3.	To approve the adoption of a proposed amended and restated Spectrum Pharmaceuticals, Inc. 2018 Long- Term Incentive Plan.	Management	For	For
4.	To ratify the selection of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For

SUTRO BIOPHARMA, INC.

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	06-Jun-2022
Record Date	12-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Michael Dybbs, Ph.D.		For	For
	2.	John G. Freund, M.D.		For	For
	3.	Heidi Hunter		For	For
	4.	Jon Wigginton, M.D.		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management	For	For
4.	To determine, on a non-binding, advisory basis, the frequency of future non-binding, advisory votes on the compensation of the Company's named executive officers.		Management	1 Year	For

SYNDAX PHARMACEUTICALS, INC.

Security	87164F105	Meeting Type	Annual
Ticker Symbol	SNDX	Meeting Date	11-May-2022
Record Date	16-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Keith A. Katkin	Management	For	For
1.2	Election of Director: Briggs W. Morrison, M.D.	Management	For	For
1.3	Election of Director: Dennis G. Podlesak	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the 2022 proxy statement.	Management	For	For
3.	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.	Management	Abstain	Against
4.	To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022.	Management	For	For

SYNEOS HEALTH, INC.

Security	87166B102	Meeting Type	Annual
Ticker Symbol	SYNH	Meeting Date	25-May-2022
Record Date	28-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Todd M. Abbrecht	Management	For	For
1B.	Election of Director: John M. Dineen	Management	For	For
1C.	Election of Director: William E. Klitgaard	Management	For	For
1D.	Election of Director: David S. Wilkes, M.D.	Management	For	For
2.	To approve an amendment to the Certificate of Incorporation to phase-out the classified board structure and provide that all directors elected at or after the 2025 annual meeting of stockholders be elected on an annual basis.	Management	For	For
3.	To approve, on an advisory (nonbinding) basis, our executive compensation.	Management	For	For
4.	To approve, on an advisory (nonbinding) basis, the frequency of future stockholder advisory votes on executive compensation.	Management	1 Year	For
5.	To ratify the appointment of the Company's independent auditors Deloitte & Touche LLP.	Management	For	For

TCR2 THERAPEUTICS, INC.

Security	87808K106	Meeting Type	Annual
Ticker Symbol	TCRR	Meeting Date	22-Oct-2021
Record Date	23-Aug-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Garry E. Menzel, Ph.D.		For	For
	2.	Ansbert Gadicke, M.D.		For	For
	3.	Neil Gibson, Ph.D.		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.		Management	For	For

THESEUS PHARMACEUTICALS INC

Security	88369M101	Meeting Type	Annual
Ticker Symbol	THRX	Meeting Date	10-Jun-2022
Record Date	14-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Iain D. Dukes		For	For
	2.	Kathy Yi		For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.		Management	For	For

TRAVERE THERAPEUTICS, INC.

Security	89422G107	Meeting Type	Annual
Ticker Symbol	TVTX	Meeting Date	11-May-2022
Record Date	18-Mar-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Roy Baynes		For	For
	2.	Suzanne Bruhn		For	For
	3.	Timothy Coughlin		For	For
	4.	Eric Dube		For	For
	5.	Gary Lyons		For	For
	6.	Jeffrey Meckler		For	For
	7.	John Orwin		For	For
	8.	Sandra Poole		For	For
	9.	Ron Squarer		For	For
	10.	Ruth Williams-Brinkley		For	For
2.	To approve the Company's 2018 Equity Incentive Plan, as amended, to, among other items, increase the number of shares of common stock authorized for issuance thereunder by 2,000,000 shares.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers.		Management	For	For
4.	To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.		Management	For	For

TRILLIUM THERAPEUTICS, INC.

Security	89620X506	Meeting Type	Special
Ticker Symbol	TRIL	Meeting Date	26-Oct-2021
Record Date	24-Sep-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To consider and, if deemed advisable, pass, with or without variation, a special resolution, the full text of which is set forth in Appendix B to the accompanying Management Information Circular and Proxy Statement of Trillium dated September 27, 2021 (the "Information Circular"), approving a statutory arrangement (the "Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) involving Trillium, all as more particularly described in the Information Circular.	Management	For	For
2.	To consider and, if deemed advisable, pass an advisory (non- binding) resolution on specified compensation that may become payable to the named executive officers of Trillium in connection with the Arrangement, all as more particularly described in the Information Circular.	Management	For	For

TSCAN THERAPEUTICS, INC.

Security	89854M101	Meeting Type	Annual
Ticker Symbol	TCRX	Meeting Date	01-Jun-2022
Record Date	12-Apr-2022

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	Timothy Barberich		For	For
	2.	Stephen Biggar		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022		Management	For	For

ULTRAGENYX PHARMACEUTICAL, INC.

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	24-Jun-2022
Record Date	26-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Lars Ekman, M.D., Ph.D.	Management	For	For
1b.	Election of Director: Matthew K. Fust	Management	For	For
1c.	Election of Director: Amrit Ray, M.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For
4.	Advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation.	Management	1 Year	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Special
Ticker Symbol	QURE	Meeting Date	21-Oct-2021
Record Date	23-Sep-2021

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Appointment of Rachelle Jacques as a non-executive director.		Management		For		For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	14-Jun-2022
Record Date	17-May-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2021 Dutch statutory annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board.	Management	For	For
3.	Resolution to reappoint Matthew Kapusta as executive director.	Management	For	For
4.	Resolution to reappoint Robert Gut as non-executive director.	Management	For	For
5.	Resolution to renew the designation of the Board as the competent body to issue ordinary shares and grant rights to subscribe for ordinary shares.	Management	For	For
6.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares.	Management	For	For
7.	Resolution to reauthorize the Board to repurchase ordinary shares.	Management	For	For
8.	Resolution to appoint KPMG as external auditor of the Company for the 2022 financial year.	Management	For	For
9.	Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company.	Management	For	For

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Special
Ticker Symbol	UTHR	Meeting Date	30-Sep-2021
Record Date	10-Aug-2021

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of an amendment to our Restated Certificate of Incorporation to become a public benefit corporation.		Management		Abstain		Against

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	27-Jun-2022
Record Date	28-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Christopher Causey	Management	For	For
1b.	Election of Director: Richard Giltner	Management	For	For
1c.	Election of Director: Katherine Klein	Management	For	For
1d.	Election of Director: Ray Kurzweil	Management	For	For
1e.	Election of Director: Linda Maxwell	Management	For	For
1f.	Election of Director: Nilda Mesa	Management	For	For
1g.	Election of Director: Judy Olian	Management	For	For
1h.	Election of Director: Martine Rothblatt	Management	For	For
1i.	Election of Director: Louis Sullivan	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2022.	Management	For	For

VECTIVBIO HOLDING AG

Security	H9060V101	Meeting Type	Special
Ticker Symbol	VECT	Meeting Date	02-Sep-2021
Record Date	06-Aug-2021

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Paul Rutherford Carter - The Board of Directors proposes to elect Paul Rutherford Carter as a new member of the Board of Directors for a term of office until completion of the 2022 Annual General Meeting of VectivBio Holding AG.	Management	For	For
2.	Dr. Murray Willis Stewart - The Board of Directors proposes to elect Dr. Murray Willis Stewart as a new member of the Board of Directors for a term of office until completion of the 2022 Annual General Meeting of VectivBio Holding AG.	Management	For	For

VECTIVBIO HOLDING AG

Security	H9060V101	Meeting Type	Annual
Ticker Symbol	VECT	Meeting Date	30-Jun-2022
Record Date	20-May-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	2021 Statutory Financial Statements and Consolidated Financial Statements - The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2021 be approved.	Management	For	For
1.2	2021 Compensation Report - The Board of Directors proposes that the 2021 Compensation Report be endorsed in a non-binding advisory vote.	Management	For	For
2.	2021 Financial Results - The Board of Directors proposes that the loss of the Company be carried forward as follows: Loss carried forward from the financial year 2020 CHF -8,709,776 Loss for the financial year 2021 CHF - 19,725,299 Loss to be carried forward CHF -28,435,075.	Management	For	For
3.	Discharge of the Board of Directors and of the Executive Committee - The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2021.	Management	For	For
4.1	Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as Chairman and member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
4.2	Sandip Kapadia - The Board of Directors proposes to re- elect Sandip Kapadia as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
4.3	Chahra Louafi - The Board of Directors proposes to re- elect Chahra Louafi as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
4.4	Paul Rutherford Carter - The Board of Directors proposes to re- elect Paul Rutherford Carter as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For

4.5	Luca Santarelli - The Board of Directors proposes to re- elect Luca Santarelli as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
4.6	Hans Schikan - The Board of Directors proposes to re- elect Hans Schikan as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
4.7	Murray Willis Stewart - The Board of Directors proposes to re- elect Murray Willis Stewart as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
5.1	Paul Rutherford Carter - The Board of Directors proposes to re- elect Paul Rutherford Carter as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
5.2	Murray Willis Stewart - The Board of Directors proposes to re- elect Murray Willis Stewart as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
5.3	Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
6.	Re-election of the Statutory Auditors - The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re- elected as the Company's statutory auditors for the financial year 2022.	Management	For	For
7.	Re-election of the Independent Proxy - The Board of Directors proposes that Buis Bürgi AG, Zürich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2023 Annual General Meeting.	Management	For	For
8.1	Maximum Aggregate Amount of Compensation of the Board of Directors - The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2022 Annual General Meeting to the 2023 Annual General Meeting of CHF 1,500,000 be approved.	Management	For	For
8.2	Maximum Aggregate Amount of Compensation of the Executive Committee - The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2023 of CHF 16,300,000 be approved.	Management	For	For
9.1	Increase and Renewal of Authorized Share Capital - The Board of Directors proposes that the Company's authorized share capital be increased and renewed to CHF 992,218.00 to enable the Board of Directors to issue up to 19,844,360 new registered shares with a par value of CHF 0.05 each until June 30, 2024, and to explicitly authorize the Board of Directors to determine as type of contribution for the capital increase(s) out of the authorized share capital any legally permitted type of ...(due to space limits, see proxy material for full proposal).	Management	For	For
9.2	Increase of the Conditional Share Capital for Participation Programs - The Board of Directors proposes that the Company's conditional share capital for participation programs be increased by CHF 159,825.75 to the maximum amount of CHF 541,332.00, allowing the issuance of up to 10,826,640 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles of Association as ...(due to space limits, see proxy material for full proposal).	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	27-Apr-2022
Record Date	15-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect Kenneth Cunningham, M.D. as a director of the Company	Management	For	For
O2	To re-elect Rishi Gupta as a director of the Company	Management	For	For
O3	To re-elect Vikas Sinha as a director of the Company	Management	For	For
O4	To re-elect James Brady as a director of the Company	Management	For	For
O5	To receive and adopt the 2021 U.K. Annual Report	Management	For	For
O6	To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report	Management	For	For
O7	To re-appoint PwC as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders	Management	For	For
O8	To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2022	Management	For	For
O9	To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £24,702,912	Management	For	For
E10	To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	18-May-2022
Record Date	24-Mar-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Sangeeta Bhatia	Management	For	For
1B.	Election of Director: Lloyd Carney	Management	For	For
1C.	Election of Director: Alan Garber	Management	For	For
1D.	Election of Director: Terrence Kearney	Management	For	For
1E.	Election of Director: Reshma Kewalramani	Management	For	For
1F.	Election of Director: Yuchun Lee	Management	For	For
1G.	Election of Director: Jeffrey Leiden	Management	For	For
1H.	Election of Director: Margaret McGlynn	Management	For	For
1I.	Election of Director: Diana McKenzie	Management	For	For
1J.	Election of Director: Bruce Sachs	Management	For	For
1K.	Election of Director: Suketu Upadhyay	Management	For	For
2.	Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2022.	Management	For	For
3.	Advisory vote to approve named executive office compensation.	Management	For	For
4.	Approval of an amendment and restatement of our 2013 Stock and Option Plan to increase the number of shares authorized for issuance under this plan by 13.5 million shares.	Management	For	For

VYNE THERAPEUTICS, INC.

Security	92941V209	Meeting Type	Annual
Ticker Symbol	VYNE	Meeting Date	19-Jul-2021
Record Date	27-May-2021

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1.	David Domzalski		For	For
	2.	Patrick LePore		For	For
2.	To ratify the selection by the Audit Committee of the Company's Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.		Management	For	For
3.	To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000.		Management	For	For

XENCOR, INC.

Security	98401F105	Meeting Type	Annual
Ticker Symbol	XNCR	Meeting Date	23-Jun-2022
Record Date	25-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Bassil I. Dahiyat, Ph.D.	Management	For	For
1.2	Election of Director: Ellen G. Feigal, M.D.	Management	For	For
1.3	Election of Director: Kevin C. Gorman, Ph. D.	Management	For	For
1.4	Election of Director: Kurt A. Gustafson	Management	For	For
1.5	Election of Director: Yujiro S. Hata	Management	For	For
1.6	Election of Director: A. Bruce Montgomery, M.D.	Management	For	For
1.7	Election of Director: Richard J. Ranieri	Management	For	For
1.8	Election of Director: Dagmar Rosa-Bjorkeson	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.	Management	For	For
3.	To hold a non-binding advisory vote on the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For

ZAI LAB LTD

Security	98887Q104	Meeting Type	Special
Ticker Symbol	ZLAB	Meeting Date	28-Mar-2022
Record Date	18-Feb-2022

Item		Proposal		Proposed by		Vote		For/Against Management
1.		THAT, the subdivision of each issued and unissued ordinary shares of the Company with a par value of US$0.00006 each into 10 ordinary shares with a par value of US$0.000006 each with effect from March 30, 2022, subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited granting the listing of, and permission to deal in, (i) the Subdivided Ordinary Shares (as defined below) (ii) any Subdivided Ordinary Shares which may be issued upon exercise of ...(due to space limits,see proxy material for full proposal).		Management		For		For

ZAI LAB LTD

Security	98887Q104	Meeting Type	Annual
Ticker Symbol	ZLAB	Meeting Date	22-Jun-2022
Record Date	25-Apr-2022

Item	Proposal	Proposed by	Vote	For/Against Management
O1	An ordinary resolution to re-elect Samantha (Ying) Du to serve as a director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.	Management	For	For
O2	An ordinary resolution to re-elect Kai-Xian Chen to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O3	An ordinary resolution to re-elect John D. Diekman to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O4	An ordinary resolution to re-elect Richard Gaynor to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O5	An ordinary resolution to re-elect Nisa Leung to serve as a director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.	Management	For	For
O6	An ordinary resolution to re-elect William Lis to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O7	An ordinary resolution to re-elect Scott Morrison to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O8	An ordinary resolution to re-elect Lonnie Moulder to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
O9	An ordinary resolution to re-elect Peter Wirth to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
S10	A special resolution to adopt the Sixth Amended and Restated Memorandum and Articles of Association of the Company in the form annexed hereto as Appendix A as described in this Proxy Statement, conditioned on and subject to the dual-primary listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited.	Management	For	For
O11	An ordinary resolution to approve the Zai Lab Limited 2022 Equity Incentive Plan, conditioned on and subject to the dual- primary listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited becoming effective.	Management	For	For
O12	An ordinary resolution to ratify the appointment of KPMG LLP ("KPMG") as the Company's independent registered public ...(due to space limits, see proxy material for full proposal).	Management	For	For
O13	An ordinary resolution, within the parameters of Rule 13.36 of the HK Listing Rules, to approve the granting of a share issue ...(due to space limits, see proxy material for full proposal).	Management	For	For
O14	An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.	Management	For	For
O15	An ordinary resolution to hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.	Management	3 Years	For

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)		Tekla Life Sciences Investors

By (Signature and Title)*

			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)

Date	8/19/22

*Print the name and title of each signing officer under his or her signature.